John Bruin

Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity

Mark Baugh, Darcey Black, Paul Westwood et al. · Journal of Autoimmunity · 2011 · 72 citations

Rheumatology, Autoimmune Disease, Medicine +9

Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments

Anja Leyte, Koen Mertens, Ben Distel et al. · Biochemical Journal · 1989 · 64 citations · Full text

Histocompatibility, Laboratory Immunology, Immunology +19

Limited clonal heterogeneity of antigen-specific T cells localizing in the pleural space during mycobacterial infection

Fabrizio Manca, Giovanni A. Rossi, Maria Teresa Valle et al. · Infection and Immunity · 1991 · 46 citations · Full text

Clinical Immunology, Immunology, Pathology +23

Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors

Zoran Ranković, Jiaqiang Cai, Jennifer Kerr et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 25 citations · Full text

Combinatorial Chemistry, Cathepsin K Inhibitors, Medicinal Chemistry +10

4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important

Jiaqiang Cai, Xavier Fradera, Mario van Zeeland et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 21 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +11